Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement

Abstract HFrEF is a debilitating disease with substantial morbidity, mortality, and costs. SGLT2i reduce adverse cardiovascular (including HF) and renal events. SGLT2i have ushered in a new treatment paradigm for HFrEF management. Collaboration between preventive cardiology and heart failure will optimize HF care. Collaboration aims to optimize CV risk factors and SGLT2i access and adherence. Article type: Research Article Keywords: Cardiovascular disease, Heart failure, Prevention, Pharmacotherapy Authors: Bruce A. Warden, Johannes Steiner, Albert Camacho, Khoa Nguyen, Jonathan Q Purnell, P.